Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
GRFS · Nasdaq · United States · Pharmaceutical Preparations
In shortGrifols SA is profitable, generates cash and carries moderate debt, with revenue growing (+9.4% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 16.5% | 72/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 2.2% | 29/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 2.8% | 14/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 11.0% | 74/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.66× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.45× | 86/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.03× | 85/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 1.67× | 2/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 9.3% | 57/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 4.27× | 100/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 10.9% | 71/100 |
| Operating margin volatility | 3.0% | 82/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 13.5% | 92/100 |
|---|---|---|
| EPS growth, 3-year average | -6.3% | 0/100 |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 5,340 | 4,933 | 6,064 | 6,592 | 7,212 |
| Cost of revenue | 3,085 | 2,971 | 3,850 | 4,108 | 4,418 |
| Gross profit | 2,255 | 1,963 | 2,214 | 2,483 | 2,795 |
| Research & development | 294 | 355 | 361 | 395 | 384 |
| Selling, general & admin | 986 | 1,062 | 1,196 | 1,373 | 1,255 |
| Operating income | 996 | 595 | 782 | 782 | 1,192 |
| Interest expense | 250 | 268 | 478 | 597 | 715 |
| Pre-tax income | 879 | 350 | 338 | 207 | 444 |
| Income tax | 170 | 85 | 90 | 43 | 231 |
| Net income | 619 | 189 | 185 | 42 | 157 |
| Diluted EPS | €0.90 | €0.28 | €0.27 | €0.06 | €0.23 |
| Diluted shares (millions) | 685 | 681 | 679 | 677 | 680 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
9/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 11, 2025